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ABSTRACT  
Chronic Renal Failure (CRF) is a slow progressive loss of 
kidney function over a period of several years. One of its 
complications that determines the patient’s quality of life is anemia. 
Blood transfusion can be used to treat anemia in patient with CRF. 
The purpose of this study are to measure the average costs per 
patient, assess the therapy outcomes, and determine the factors 
that influence the cost of blood transfusion in anemia treatment for 
patients with CRF in A, B, and C hospitals. This study was a 
descriptive non-experimental research. Cost analysis was based on 
the perspective of the hospital. Data were obtained retrospectively 
from medical records and payment details of inpatient with CRF who 
experienced anemia in A (tertiery hospital in Yogyakarta province), 
B (tertiary hospital in Central Java province), and C (private hospital 
in the province of Yogyakarta) hospitals. Data was analysed by 
calculating the average costs per patient, while therapy outcome 
was measured by calculating the percentages of patients who 
achieved the target of hemoglobin level. Furthermore, the factors 
that influenced the amount of the total cost were analysed using 
Oneway ANOVA and Independent T-Test for data with normal 
distribution and the Kruskal-Wallis and Mann-Whitney for data with 
non-normal distribution. The results showed that the average costs 
per patient for anemia treatment in patient with CRF who had blood 
transfusion therapy were Rp 8,873,243.39±4,417,825.83 in A 
hospital, Rp 5,249,464.97±4,283,655.41 in B hospital; and Rp 
7,961,088.00±6,105,501.80 in C hospital. Most of the patients in A, 
B, and C hospitals had achieved the target of hemoglobin level 
(>7g/dL) with the percentages of 95.56%, 68.57% and 87.50% 
respectively. The factors that mainly influenced the cost of anemia 
treatment in CRF are length of hospitalization for A hospital, age, 
gender, payment models, and length of hospitalization for B 
hospital, whereas age and length of hospitalization for C hospital. 
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INTRODUCTION 
Chronic renal failure (CRF) is one of 
major health problems in society that requires 
high expenditure in the health care system. 
Patients with CFR have high risk of suffering 
from concomitant diseases (comorbid) such as 
cardiovascular disease (Carroll, 2006). 
National Health and Nutrition 
Examination reported that the prevalence of 
CRF increased from 10% to 13% over 10 years 
between 1994 and 2004 (Abboud and Henric, 
2010). CRF incidences increased with average 
of 8% per year (Novoa et al., 2010). CRF affects 
approximately 26 million people in United State 
(Lankrst and Wish, 2010). 
Therapy for CRF requires enormous 
cost. According to United Stated Renal Data 
System explained that in 2010 the total costs 
for patients with CRF were 3.35 billion dollars 
in which 8% of the total cost incurred on CRF 
stages 1-2, 35% occurred in stage 3, and 13% 
occured in stage 4-5. Overall expenses of 
medical care for patients with CRF was around 
41 billion dollars, and the cost per person per 
year estimated around 22,323 dollars for all 
chronic renal failure (USRDS, 2012). 
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Anemia is a major complication in renal 
disease and occurs almost in patient with CRF. 
Anemia increase the risk of renal impairment, 
lowering quality of life, and decreasing the risk 
factor for premature death (Lankrst and Wish, 
2010). Anemia is also one of the most 
conditions that lead to death and disability in 
the world (Acomb, 2003; Masood and Teehan, 
2012). Moreover, it will increase the healthcare 
cost (Dalton and Schmidt, 2008). 
National Health and Nutrition 
Examination Survey (NHANES) conducted by 
the National Institutes of Health and the 
Prevalence of Anemia in Early Renal 
Insufficiency (PAERI) reported that the 
incidence of anemia in chronic renal failure 
approximately <10% in stage 1 and 2, 20-40% 
at stage 3, 50-60% in stage 4, and >70% at 
stage 5 (Lankrst and Wish, 2010). The 
incidence of anemia will increase with the 
decreasing of glomerulo filtration rate (GFR) 
(Lankrst and Wish, 2010; Dalton and Schmidt, 
2008). 
Anemia as a result of kidney disease is 
treated mainly with erythropoietin (Gombotz, 
2012). Although erythropoietin has many 
advantages but it is an expensive drug. It makes 
obstacle for patient to get this drug (Mikhail et 
al., 2012 ). Blood transfusion is still used as 
anemia treatment for patient with CRF, despite 
of having the disadvantages such as the high 
possibility of reactions due to the transfusion, 
vulnerable transmission of hepatitis B and C, 
and potential medical error (Hudson, 2008). On 
the other hand blood transfusion has several 
advantages such as rapidly increasing Hb levels 
to the normal range, increasing blood volume, 
and improving oxygen delivery to the tissues so 
it can reduce several symptoms such as fatigue 
and dizziness (Sharma et al., 2011; Gombotz, 
2012). 
The purpose of this study were to assess 
the outcome of therapy and the total cost 
during blood transfusion therapy, and identify 
the factors that determine the cost of anemia 
treatment in patient with CRF. 
 
MATERIAL AND METHODS 
Subjects research 
Subjects were inpatients with CRF who 
had   anemia in    A,  B,  C  hospitals   in   2012.  
Inclusion criterias were patients who was 
diagnosed with CRF and anemia, got a blood 
transfusion therapy, had complete medical 
records, and available payment data. Exclusion 
criteria was patient who died while undergoing 
treatment at the hospital. There were 45 cases 
in  hospital A (tertiary hospital in the province 
of Yogyakarta), and 70 cases at Hospital B 
(tertiary hospital in Central Java province) and 
40 cases in the hospital C (private hospitals in 
the province of Yogyakarta), that met the 
inclusion and exclusion criteria. 
 
Research data 
Data obtained from medical records 
included age, gender, treatment class, payment 
models, length of stay, stage of CRF, and 
hemoglobin level. Data for patient care costs 
was taken from the financial department.              
Cost analysis was based on the perspective             
of the hospital. Data were obtained 
retrospectively from medical records and 
payment details of inpatient with CRF who 
experienced anemia. 
Outcome of blood transfusion therapy 
were calculated based on the percentages of 
patients who achieved the target of hemoglobin 
levels after receiving blood transfusion or 
hemoglobin levels when patients discharged 
from hospital. Targeted therapy in blood 
transfusion if the achievement of Hb ≥7. Hb 
level of data obtained from the medical records 
of patients. 
 
Analysis of research findings 
Patients were classified by age, gender, 
treatment class, payment models, long 
hospitalization, stage of CRF, and Hb levels 
when patients entered hospital before 
treatment. Outcome analysis of blood 
transfusion therapy was calculated based on the 
percentage of patients who achieved Hb 
>7g/dL when patients discharged from 
hospital. After that, the average of total cost for 
inpatient treatment and the factors that 
influence the amount of the total cost                
were analysed using One -way ANOVA               
and Independent T -Test for data with         
normal distribution and the Kruskal-Wallis and 
Mann-Whitney for data with non-normal 
distribution. 
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RESULTS AND DISCUSSIONS 
Patient characteristics 
Male patients were higher than females 
with the percentage of 53.33%, 58.82%, and 
62.50% in A, B, and C hospitals respectively. 
The incidence of anemia in CRF is more 
common in men than women, because the 
kidney damage occurs more quickly in men 
than in women (McFarlane et al., 2008). Other 
cross-sectional study from the National Health 
and Nutrition Examination Survey explain that 
the prevalence of chronic renal failure in males 
is higher than females so the risk of anemia also 
be more common in males. 
The majority of patients both in A, B, 
and C hospitals were hospitalized in the third 
class with the percentages of 77.15%, 73.34%, 
and 65.00% respectively. According to the 
payment models, most of patients in A and B 
hospitals were financed by health insurance for 
the poor (JAMKESMAS) with the same 
percentages of 40.00% (18 and 28 patients 
respectively), while in C hospital the majority of 
patients paid with their own money with the 
percentages of 35.00% (14 patients). Based on 
the length of hospitalization, the majority of 
patients were hospitalized in the range of 6-10 
days with with the percentages of 55.56% (25 
days), 44.29% (31 days ), and 45.00% (18 days) 
in A, B, and C hospitals respectively. 
The majority of patients were diagnosed 
CRF at stage 5 with the percentages of 95.56% 
(43 cases) in A hospital, 94.28% (66 cases) in 
the B hospital, and 92.50% (37 cases in C 
hospital. This is accordance with a study from 
the National Health and Nutrition Examination 
Survey ( NHANES ) by the National Institutes 
of Health and Prevalence of Anemia in Early 
Renal Insufficiency (PAERI) showed that the 
incidence of anemia was less than 10% in stage 
I of CRF and II, 20-40% in stage III, 50-60% 
in stage IV, and more than 70% in stage V ( 
Lankrst and Wish, 2010), so there were an 
increase in the incidence of anemia with 
increasing the stage of CRF both in all three 
hospitals. 
The majority of patients with anemia in 
chronic renal failure admitted to hospital with 
Hb<7g/dL i.e. in the A hospital with 24 cases 
(53.33%), B hospital with 44 cases (62.86%), 
and C hospital with 19 cases ( 47.50% ). 
 
Blood transfusion therapy outcome 
Outcome of blood transfusion therapy 
were calculated based on the percentages of 
patients who achieved the target of hemoglobin 
levels after receiving blood transfusion or 
hemoglobin levels when patients discharged 
from hospital. Therapy outcome is determined 
to control the patient's hemoglobin levels 
within the normal range in order to prevent the 
complications that can be caused by               
anemia. The target of blood transfusion is to 
achieve hemoglobin levels at 7-9 g/dL (not the 
same as the hemoglobin target in ESA           
therapy) (PERNEFRI, 2012). The number of 
patients who had achieved the target of 
hemoglobin level at each hospital is showed in 
table I. 
According to table I, the majority               
of patients in the Hospital A, Hospital B,            
and Hospital C had achieved the target                 
of hemoglobin levels (>7g/dL) with the 
percentages of 95.56%, 68.57% and 87.50% 
respectively. In addition, treatment outcome 
was also analysed in the increase of hemoglobin 
levels after patients received blood transfusions. 
Table II explained that in all hospitals most of 
patients experienced an increase in hemoglobin 
levels after receiving blood transfusion. 
However, in some cases both of A and C 
hospital there were a decrease in hemoglobin 
levels due to the fact that CRF is a progressive 
kidney disease in which the anemic condition 
will get worse with worsening of kidney disease, 
so the decline of hemoglobin levels could be 
occured even after receiving blood transfusion 
treatment. 
 
Cost analysis 
This study looked at a total cost of 
treatment of patients, its components, and how 
big the components that contribute to the 
magnitude of the total cost. These costs are 
calculated by looking at the average cost to be 
incurred by each patient admissions each 
component described. Analysis was performed 
on blood transfusion costs, examinations, 
hospital services, the anemia drug drugs for 
other diseases, medical devices, drug charges 
anemia, dialysis, surgery, and non-medical 
costs. 
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Cost analysis was conducted to 
determine which component is the largest 
allocation for the anemia treatment in the 
hospital, the percentages of blood  transfusion 
cost compared to total cost, and the average of 
total costs per patient in A, B, and C hospitals. 
According to the table III, the average of 
total costs per patient for treating anemia in 
CFR were Rp 5,249±4,283million, Rp 
7,961±6,105 million, and Rp 8,873±4,417 
million in B, C, and A hospitals respectively. 
The highest budget allocation in the B hospital 
was examination fees (26.78%), while in the C 
and A hospitals the highest proportion were the 
cost of operating with 42.49% and 32.25% 
respectively. Examination fee in hospital C and 
A of 8.96% and 27.77%. The examination fees 
included USG, laboratory test, radiology and 
EKG. Cost of blood transfusions allocated 
12.53% in the B hospital, 10.24% in C hospital, 
Table I. Patients who achieved targeted therapy. 
 
Hospital C Hospital A Hospital B 
Categori Hb 
n=40 % n=45 % n=70 % 
≤7 g/dL (not achieved the target) - - 1 2.22 14 20.00 
>7 g/dL (achieved the target) 35 87.50 43 95.56 48 68.57 
Not Available 5 12.50 1 2.22 8 11.43 
Total 40 100.00 45 100.00 70 100.00 
 
Table II. Patients who experiencing increase in hemoglobin levels. 
 
Hospital C Hospital  A Hospital B 
Categori Hb 
n=40 % n=45 % n=70 % 
Increase 29 72.50 35 77.78 61 87.14 
Fixed - - 1 2.22 - - 
Decrease 3 7.50 8 17.78 - - 
Not Available 8 20.00 1 2.22 9 12.86 
Total 40 100.00 45 100.00 70 100.00 
 
Table III. Cost components of anemia treatment in inpatients with CRF who received blood 
transfusion in A, B and C Hospitals in 2012. 
 
Hospital B Hospital C Hospital A 
Cost Components 
Average Cost 
per Patient±SD 
(million Rp) 
% 
Average Cost 
per Patient±SD 
(million Rp) 
% 
Average Cost 
per Patient±SD 
(million Rp) 
% 
Transfusion 0.659±0.452 12.53 0.815±0,011 10.24 0.837±0.395 9.44 
Examinations 1.406±0.863 26.78 0.713±0.727 8.96 2.461±1.235 27.77 
 Anemia drugs 0.006±0.005 0.11 0.022±0.021 0.28 0.010±0.005 0.11 
Medical services 0.422±0.355 8.04 0.407±0.408 5.11 0.867±0.545 9.78 
Other disease drugs 0.902±1.776 17.19 1.337±2.611 16.80 1.366±1.568 15.41 
Administration 0.016±0.039 0.31 0.078±0.024 0.98 0.015±0.007 0.17 
Surgery - - 3.382±1.650 42.49 2.858±1.935 32.25 
Hemodyalisis 0.965±1.111 18.38 1.394±0.737 17.51 1.715±0.825 19.35 
Services 0.217±0.352 4.14 0.188±0.210 2.36 0.468±0.467 5.28 
Hospitalizations 0.448±0.351 8.54 0.990±0.923 12.44 1.026±1.163 11.58 
Medical devices 0.511±0.625 9.73 0.198±0. 299 2.49 0.444±0.318 5.01 
The others 0.049±0.018 0.94 0.010±0 0.19 0.033±0.015 0.37 
Averge total cost 
per patient 
5.249±4.283  7.961±6.105  8.873±4.417  
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and 9.44% in A hospital. Other costs that 
require a large allocation in all three hospitals 
were hemodialysis and drugs for other diseases. 
Costs of other diseases had high contribution 
since the majority of patients had comorbid 
diseases and complications. 
 
Factors that influence the total costs for 
treating 
Analysis of factors that influence the 
total cost of treating were analysed using 
One -way ANOVA and Independent T-test 
for data with normal distribution and the 
Kruskal-Wallis and Mann-Whitney for data 
data with non-normal distribution. If significant 
value (p) is less than 0.05, the factors influence 
the total cost of treating significantly. The 
results showed that A hospital is affected by the 
length of stay (LOS) with p=0.000; the hospital 
B is influenced by age (p=0.040), gender 
(p=0.035), the payment models (p=0.001), and 
LOS (p=0.000); and C hospital is influenced by 
age (p=0.001) and LOS (p=0.000). It can be 
interpreted that if there is an increase in the 
length of hospitalization, the total cost will 
increase significantly. 
 
CONCLUSION 
In conclusion, the average costs per 
patient for anemia treatment in patients with 
CRF using blood transfusion therapy were Rp 
8,873,243.39±4,417,825.83 in A Hospital, Rp 
5,249,464.97±4,283,655.41 in B Hospital, and 
Rp 7.961.088,00±6,105,501.80 in C Hospital. 
The majority of patients in A, B, and C 
hospitals had achieved the target of 
hemoglobin levels (>7g/dL) with the 
percentages of 95.56%, 68.57% and 87.50% 
respectively. The factors that mainly influenced 
the cost of anemia treatment in CRF are length 
of hospitalization for A hospital, age, gender, 
payment models, and  length of hospitalization 
for B hospital, whereas age and length of 
hospitalization for C hospital. 
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